within Pharmacolibrary.Drugs.ATC.L;

model L03AX18
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L03AX18</td></tr><td>route:</td><td></td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Cridanimod is an antiviral and immunomodulatory drug previously developed in Russia, belonging to the category of interferon inducers. It has been historically used for treatment of viral infections and oncology adjunct applications, but is not currently approved or widely used in modern medical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are not reported in the existing literature for humans. No peer-reviewed publications provide values for key PK parameters such as volume of distribution, clearance, or absorption rate. Thus, below parameters are left empty or estimated.</p><h4>References</h4><ol><li><p>Bazhanova, ED (2012). [Cycloferon: mechanism of action, functions and application]. <i>Eksperimental&#x27;naia i klinicheskaia farmakologiia</i> 75(7) 40–44. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23025052/&quot;>https://pubmed.ncbi.nlm.nih.gov/23025052</a></p></li><li><p>Han, X, et al., &amp; Dai, L (2025). Discovery of an Orally Bioavailable STING Inhibitor with In Vivo Anti-Inflammatory Activity in Mice with STING-Mediated Inflammation. <i>Journal of medicinal chemistry</i> 68(3) 2963–2980. DOI:<a href=&quot;https://doi.org/10.1021/acs.jmedchem.4c02200&quot;>10.1021/acs.jmedchem.4c02200</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39875322/&quot;>https://pubmed.ncbi.nlm.nih.gov/39875322</a></p></li><li><p>Taylor, JL, et al., &amp; Grossberg, SE (1980). High-yield interferon induction by 10-carboxymethyl-9-acridanone in mice and hamsters. <i>Antimicrobial agents and chemotherapy</i> 18(1) 20–26. DOI:<a href=&quot;https://doi.org/10.1128/AAC.18.1.20&quot;>10.1128/AAC.18.1.20</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6158292/&quot;>https://pubmed.ncbi.nlm.nih.gov/6158292</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L03AX18;
